Delivery Order SPE2DR25D2203-SPE2DR26FD2SY
- Not listed
- This is a $1,471.80 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of LIALDA DR 1.2 GM TABLET 120S, a pharmaceutical product. The contract has a completion date of July 10, 2025 and is not set aside for any specific business type. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the...
- This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $9,714.39 firm fixed-price delivery order is for the supply of LIALDA DR 1.2 GM TABLET 120S, a pharmaceutical product. The contract has an ultimate completion date of October 13, 2023. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order on July 24, 2025, for LIALDA DR 1.2 GM Tablet 120s, a pharmaceutical product used in the treatment of inflammatory bowel disease. This competitively awarded, firm fixed-price contract carries a ceiling value of $8,154.24 and is scheduled for completion by July 25, 2025. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the provision of LIALDA DR 1.2 GM TABLET 120S. The contract has a firm fixed price of $3,236.85 and a period of performance through March 14, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 25, 2025, for the supply of LIALDA (mesalamine) 1.2 GM tablets in a quantity of 120 units, with a ceiling value of $1,992.91 under a firm fixed-price contract type. This delivery order represents a child contract executed under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) designated SPE2DX with DLA Troop Support Medical, valued at $999,999,999.00 and extending through...
- Amerisourcebergen Drug Corp has received a firm fixed price delivery order from the Defense Logistics Agency Troop Support Medical to supply LIALDA DR 1.2 GM tablets. The order, valued at $2,444.37, requires delivery of 120 tablets to a facility located in Conshohocken, Pennsylvania by November 21, 2023. No set aside designation was applied to this award made against an indefinite delivery contract held by Amerisourcebergen Drug Corp to provide pharmaceuticals and medical supplies to various...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4566760943 - LIALDA DR 1.2 GM TABLET 120S, a prescription medication. The contract is a Firm Fixed Price Delivery Order with a ceiling value of $1,922.17 and a completion date of December 19, 2024. The award is not designated as a set-aside contract. AmerisourceBergen holds a...
- This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $3,300.51, is a Delivery Order for the medical product "LIALDA DR 1.2 GM TABLET 120S". The contract has a Firm Fixed Price pricing type and an ultimate completion date of December 16, 2024. This award is not designated as a set-aside contract. Amerisourcebergen holds...
- This federal contract award is for the delivery of Lialda DR 1.2 GM Tablet (120s) to the Defense Logistics Agency (DLA), a component of the U.S. Department of Defense. The $2,613.18 firm fixed-price contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on September 8, 2021, with a completion date of September 9, 2021. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen Drug Corp holds with the DLA Troop...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the provision of 4,566,150 units of the prescription drug Lialda (mesalamine) in 120-count tablet bottles. The $2,807.73 firm fixed-price contract has an ultimate completion date of October 21, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical division, which serves as a primary vehicle...
- SPE2DR25D2203Indefinite Delivery Contract
- SPE2DR25D2203-SPE2DR26FD2SYDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,351.56 to AmerisourceBergen Drug Corp for LIALDA DR 1.2 GM tablets (120-count supply) on December 17, 2025, with completion scheduled for December 18, 2025. This is a firm fixed-price delivery order with no set-aside designation, awarded competitively under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX). The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a routine pharmaceutical procurement supporting federal medical supply needs for military and veteran healthcare systems. AmerisourceBergen, a major pharmaceutical distributor and critical vendor for federal medical procurement, maintains an extensive IDC with DLA valued at $999,999,999.00 through December 2026, which serves as the overarching vehicle for delivering a comprehensive range of pharmaceutical products and medical supplies globally. The company's federal contract portfolio demonstrates consistent capability in fulfilling competitive medical procurement requirements across diverse therapeutic domains for the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 12/16/25 |